文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

人类癌症嵌合抗原受体(CAR)T细胞免疫治疗简介

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
PubMed 文献 · Am J Hematol · 2019-02-18

本文综述了CAR T细胞疗法的概念,即对患者自身T细胞进行基因工程改造以表达靶向肿瘤抗原的合成受体,扩增后回输以攻击耐化疗肿瘤。在B细胞恶性肿瘤中观察到显著临床反应和高完全缓解率,促使FDA批准两种靶向CD19的CAR T细胞用于治疗急性淋巴细胞白血病和弥漫性大B细胞淋巴瘤。文章还讨论了该领域的挑战、生物标志物在预测临床反应中的效用以及下一代CAR T细胞方法的前景。

要点

  • CAR T细胞疗法是个性化癌症治疗的重要进展,通过基因工程改造患者自身T细胞表达靶向肿瘤抗原的合成受体。
  • 在B细胞恶性肿瘤中观察到显著临床反应和高完全缓解率,FDA已批准两种靶向CD19的CAR T细胞产品。
  • 文章讨论了该领域的挑战、生物标志物在预测临床反应中的效用以及下一代CAR T细胞方法的前景。

核心结论

  • CAR T细胞疗法是合成生物学和个性化细胞癌症治疗首批成功商业化范例之一,在B细胞恶性肿瘤中观察到显著临床反应和高完全缓解率。

研究设计与样本

  • 本文为综述,介绍利用CAR T细胞打破对肿瘤的免疫耐受的概念,并讨论该领域的挑战、生物标志物在预测临床反应中的效用以及下一代CAR T细胞方法的前景。

主要发现

  • 在CAR T细胞治疗B细胞恶性肿瘤中观察到显著临床反应和高完全缓解率。
  • FDA近期批准两种靶向CD19蛋白的CAR T细胞,分别用于治疗急性淋巴细胞白血病和弥漫性大B细胞淋巴瘤。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR T cells are then expanded for clinical use and infused back into the patient's body to attack and destroy chemotherapy-resistant cancer. Dramatic clinical responses and high rates of complete remission have been observed in the setting of CAR T-cell therapy of B-cell malignancies. This resulted in two recent FDA approvals of CAR T cells directed against the CD19 protein for treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Thus, CAR T cells are arguably one of the first successful examples of synthetic biology and personalized cellular cancer therapy to become commercially available. In this review, we introduce the concept of using CAR T cells to break immunological tolerance to tumors, highlight several challenges in the field, discuss the utility of biomarkers in the context of predicting clinical responses, and offer prospects for developing next-generation CAR T cell-based approaches that will improve outcome.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019. PMID: 30680780. doi:10.1002/ajh.25418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。